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The g-secretase complex comprises presenilin (PS), nicastrin (NCT), anterior pharynx-defective 1
(Aph1), and presenilin enhancer 2 (Pen2). PS has two homologues, PS1 and PS2. Aph1 has two isoforms,
Aph1a and Aph1b, with the former existing as two splice variants Aph1aL and Aph1aS. Each complex
consists of one subunit each, resulting in six different g-secretases. To better understand the functional
differences among the g-secretases, we reconstituted them using a yeast system and compared Notch1-
cleavage and amyloid precursor protein (APP)-cleavage activities. Intriguingly, PS2/Aph1b had a clear
substrate speciﬁcity: APP-Gal4, but not Notch-Gal4, was cleaved. In HEK cell lines expressing deﬁned g-
secretase subunits, we showed that PS1/Aph1b, PS2/Aph1aL, PS2/Aph1aS and PS2/Aph1b g-secretase
produced amyloid b peptide (Ab) with a higher Ab42þAb43-to-Ab40 (Ab42(43)/Ab40) ratio than the
other g-secretases. In addition, PS2/Aph1aS g-secretase produced less Notch intracellular domain
(NICD) than did the other 5 g-secretases. Considering that the Ab42(43)/Ab40 ratio is relevant in the
pathogenesis of Alzheimer's disease (AD), and that inhibition of Notch cleavage causes severe
side effect, these results suggest that the PS2/Aph1aS g-secretase complex is a potential therapeutic
target in AD.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The aspartyl-protease g-secretase produces amyloid b peptide
(Ab), a causative protein in Alzheimer's disease (AD). Ab is pro-
duced after sequential cleavage of the amyloid b precursor protein
(APP) by b-secretase (BACE1) and g-secretase. Initially, APP is
cleaved by BACE1 to produce a C99 fragment, which is further
cleaved by g-secretase [1]. g-secretase cleaves the C99 fragment at
several sites, including the 3site and the subsequent g site [2].
Cleavage at the 3site produces Ab49 or Ab48, depending on which
side of the site cleavage occurs. Ab49 is processed to Ab40 via the
release of three tripeptides (ITL, VIV, and IAT), while Ab48 is pro-
cessed to Ab42 via the release of two tripeptides (VIT and TVI) [3],
indicating tripeptidylcarboxypeptidase activity of g-secretase. Abisha University, 1-3 Tatar-
hiura).
Inc. This is an open access article uin the human brain consists mainly of Ab40 and Ab42 at a ratio of
approximately 9:1. Ab42 is more prone to aggregate [4], and an
increase in the Ab42-to-Ab40 ratio (Ab42/Ab40), observed in fa-
milial AD patients, is believed to lead to AD pathology [5].
Furthermore, Ab43 is another neurotoxic Ab species and PS with
familial AD mutations causes higher Ab43/Ab40 ratios [6]. Because
the Ab42(43)/Ab40 ratio is determined by g-secretase, investiga-
tion of g-secretase may help elucidate the pathogenesis of AD.
The g-secretase complex comprises four core subunits: pre-
senilin (PS), nicastrin (NCT), anterior pharynx-defective 1 (Aph1),
and presenilin enhancer 2 (Pen2) [7,8]. PS is the catalytic subunit of
g-secretase, and many PS mutations associated with familial AD
result in a high Ab42/Ab40 ratio [5]. PS has two homologues, PS1
and PS2, and Aph1 has two isoforms: Aph1a, with splicing variants
Aph1aL and Aph1aS, and Aph1b. Because g-secretase contains only
one molecule of each subunit [9], at least six different g-secretase
complexes may occur in vivo. The functional differences among
these complexes are only partially known.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and substrate speciﬁcity of the g-secretase complexes, using yeast
as a model system [10e12] and human HEK293 cells. Because yeast
lacks endogenous g-secretase, we reconstituted puriﬁed human g-
secretases in yeast and compared their respective activities. Our
data suggest that different combinations of PSs and Aph1s result in
different g-secretase functions.2. Materials and methods
2.1. Constructs
To express six different g-secretases and Gal4 fusion substrates
in yeast, PS (PS1 or PS2), NCT, Aph1-HA (Aph1aL-HA or Aph1aS-HA
or Aph1b-HA), Flag-Pen2 and C55-Gal4 or Notch-Gal4 were cloned
into the pBEVY, as described previously [11]. An Aph1b clone (GNP
Clone IRAL037F15) was provided by the RIKEN Bio Resource Center,
which participates with the National Bio Resource Project of the
Ministry of Education, Culture, Sports, Science and Technology of
Japan [13e16].2.2. Yeast transformation and reporter assays
To reconstitute each g-secretase complex, three plasmids were
transformed into Saccharomyces cerevisiae strain PJ69-4A (MATa,
trp1-901, leu2-3, 112, ura3-52, his3-200, gal4d, gal80d, LYS2:GAL1-
HIS3, GAL2-ADE2, met2:GAL7-lacZ) [17]. The transformants were
selected on SD-LWU plates.
The expression of Gal reporters HIS3 (His), ADE2 (Ade), and lacZ
were estimated via growth assays on SD-LWHUAde plates and b-
galactosidase activities. The b-galactosidase assays were performed
as described previously [11,12].2.3. Cell lines and transfection
Human embryonic kidney (HEK293) cell lines stably expressing
Swedish mutant APP and g-secretase [18] were kindly provided by
Harald Steiner. Brieﬂy, PS1 or PS2, respectively, is stably transfected
into Aph-1 double knockdown HEK293 cells already stably
expressing APH-1aL, -aS or -1b and Swedishmutant APP. Cells were
maintained in Dulbecco's Modiﬁed Eagle's Medium supplemented
with 10% foetal bovine serum and G418 (200 mg/ml), Hygromycin B
(100 mg/ml), Blasticidin (10 mg/ml), Zeocin (400 mg/ml), Puromycin
(0.5 mg/ml), 1% Penicillin-Streptomycin.2.4. ELISA
To detect levels of Ab40, Ab42 and Ab43 secreted in the culture
media, human Ab40, Ab42 and Ab43 assay kits (IBL international
RE59781, RE59791 and RE59711, respectively) were used. ELISAwas
performed according to the instruction manual. Culture media
were diluted 250-fold, 20-fold and 5-fold for the Ab40, Ab42 and
Ab43 ELISA, respectively. Three independent samples from each
cell lines were tested for each Ab.2.5. Antibodies
The following antibodies were used for immunoblotting: poly-
clonal antibodies against NCT (N1660), Pen2 N-terminus (1638),
PS1 loop region (3027) [20], Aph1a L/S loop (O2F1, PRB-551P),
Aph1b C-terminus (435) [21], Ab (2D8), APP C-terminus (6687),
b-actin (Abcam, ab8227), and monoclonal antibodies against PS2
(BI.HF5c) [22], GFP (Clontech, 632381).3. Results
3.1. PS2/Aph1b g-secretase cleaves APP- but not Notch-derived
substrates in a yeast reconstitution system
To compare the APP- and Notch-cleavage activities of the six
different g-secretases, we introduced PS (PS1 or PS2), NCT, Aph1
(Aph1aL-HA or Aph1aS-HA, or Aph1b-HA), and Flag-Pen2 into the
yeast strain PJ69-4A [17]. This strain expresses HIS3, ADE2, and lacZ
under Gal4 control. As a substrate for g-secretase, C55-Gal4 (‘C55’
indicates amino acids 672e726 of human APP770 isoform) or
Notch-Gal4 (‘Notch’ indicates amino acids 1703e1754 of mouse
Notch1) was co-expressed. Transformants expressing different g-
secretases (PS1/Aph1aL, PS1/Aph1aS, PS1/Aph1b, PS2/Aph1aL, PS2/
Aph1aS or PS2/Aph1b) were streaked on SD media plates lacking
Leu, Trp, and Ura (SD-LWU) and SD media plates lacking Leu, Trp,
His, Ura, and Ade (SD-LWHUAde). Yeast growth was observed 3
days after streaking. Growth of yeast cells only occurs upon
cleavage of Gal4 containing substrate.
We ﬁrst tested cleavage efﬁciency of APP-derived substrate,
C55-Gal4, by six different g-secretases. Yeast expressing PS1 g-
secretase with any of the Aph1 subunits grew well on SD-
LWHUAde, indicating efﬁcient processing by g-secretase. In
contrast, yeast expressing PS2 g-secretase grew poorly, with the
exception of PS2/Aph1b, indicating that PS2/Aph1aL or S isoforms
do not efﬁciently process C55-Gal4. (Fig. 1a). The b-galactosidase
activity of the yeast lysates conﬁrmed that all PS1 containing g-
secretases but only PS2/Aph1b g-secretase efﬁciently cleaved APP
(Fig. 1c).
Next, we evaluated whether cleavage of the Notch-Gal4 was
affected by different PSs and Aph1s. Yeast expressing PS1 g-secre-
tase grew normally on the SD-LWHUAde plates, whereas yeast
expressing any of the PS2 g-secretases grew poorly, implying that
PS1 g-secretase cleaves Notch-Gal4 more efﬁciently than PS2 g-
secretases (Fig. 1b). The b-galactosidase activities of the yeast ly-
sates conﬁrmed the growth assay. A high level of b-galactosidase
activity was observed in the lysates from transformants expressing
PS1 g-secretase, with the PS1/Aph1aS variant showing the highest
activity. In contrast, low activity was observed in the lysates from
transformants expressing PS2 g-secretase (Fig. 1c). The Aph1 iso-
mer appeared to have no signiﬁcant effect on the activities of the
PS2 g-secretases (Fig. 1c). These two results from yeast Gal4 re-
porter assays suggest that combinations of PSs and Aph1s
contribute to substrate speciﬁcity.
3.2. PS2 g-secretases produce Ab with higher Ab42(43)/Ab40 ratio
in HEK293 cells stably expressing 6 different g-secretases
Different substrate speciﬁcities for Notch and APP in yeast
prompted us to check the substrate speciﬁcities of distinct g-sec-
retases in mammalian cells. To this end, we analysed Ab production
by each g-secretase using HEK293/Swe cells stably expressing each
combination of PSs and Aph1s [23]. HEK293/Swe are human kidney
cells stably expressing APPswe, a mutated APP that produces high
amounts of Ab. Ab in the culture media of each line was collected
for 6 h, and cells were harvested. Expression levels of different
combinations of PSs and Aph1s were conﬁrmed by Western blot
analysis, showing that each cell lines express almost single g-sec-
retase (Fig. 2). Long exposure blots of Fig. 2 showed that there are
almost no residual expressions of Aph1, whereas there are slight
residual expressions of PSs (Supplementary Fig. S1). Importantly,
each cell line also expresses similar amount of C99, the substrate of
g-secretase to produce Ab (Fig. 2). The amounts of Ab released into
the culture media were analysed by Enzyme-Linked Immuno-sor-
bent Assay (ELISA) for Ab40, Ab42 and Ab43. Cells expressing PS1/
Fig. 1. Gal4 reporter assays in a yeast reconstitution system. a and b, yeast cells were transformed with PS (PS1 or PS2), NCT, FLAG-Pen2, Aph1 (Aph1aL-HA, Aph1aS-HA, or
Aph1b-HA), and C55-Gal4 (a), or Notch-Gal4 (b). Three independent clones were streaked and cultured on SD-LWU or SD-LWHUAde media at 30 C for 3 days. c, b-galactosidase
activity was measured using each yeast lysate. Lysates were prepared from yeast cells expressing C55-Gal4 or Notch-Gal4 using glass beads. One unit of b-galactosidase activity
corresponds to 1 nmol O-nitrophenyl b-D-galactopyranoside hydrolysed min1, and activity was expressed as units min1 (mg of protein in lysate)1. Statistical analyses were
performed by one-way analysis of variance followed by Tukey's multiple comparison test. The data are presented as means ± SD (n ¼ 3), *p < 0.05, ***p < 0.001, ****p < 0.0001.
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of Ab40, Ab42 and Ab43, respectively, suggesting that g-secretase
with Aph1aS produces more Ab than the other complexes. Only
in the case of Ab43, PS1/Aph1b secretes slightly more Ab than PS2/
Aph1aS (Fig. 3aec). Consequently, the total amount of Abproduction (Ab40, Ab42 and Ab43) in HEK293/Swe cells expressing
Aph1aS g-secretases was higher than those in cells expressing
Aph1aL and Aph1b (Fig. 3d). In contrast, g-secretases containing
Aph1aL produced the lowest amounts of Ab40, 42, 43, respectively
(Fig. 3aec), reﬂected also in lowest total production in Fig. 3d. These
Fig. 2. HEK293 cells expressing distinct g-secretase by different combinations of
PSs and Aph1s. HEK293 cells stably expressing the six distinct g-secretases were
plated on 60 mm dish and cultured until ~100% conﬂuency and, incubated at 37 C for
another 6 h after the culture media was replaced with new media. Thereafter media
and cell lysates were prepared and subjected to Western blot analysis with speciﬁc
antibodies as indicated. For checking C99 levels, cells were treated with g-secretase
inhibitor, L-685,458 (1 mM), for 18 h.
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Fig. S2).
Next, the Ab42(43)/Ab40 ratios, important for the pathogenesis
of Alzheimer's disease, were calculated. HEK293/Swe cells
expressing PS1 g-secretase with Aph1aL or Aph1aS produced Ab
with lower Ab42(43)/Ab40 ratio than did the cells expressing the
four other g-secretase variants (Fig. 3e). These results from ELISA
implied that all PS2 g-secretases produced Ab in higher Ab42(43)/
Ab40 ratio than did PS1/Aph1aL g-secretase (Fig. 3e). The data
suggest that PS2 contributes to higher Ab42(43)/Ab40 ratios or
alternatively that Aph1a contributes to lower ratios in PS1 g-sec-
retase. Processing of Ab43 to Ab40 by each g-secretase was also
tested. PS1/Aph1b g-secretase showed lower efﬁciency of conver-
sion of Ab43 to Ab40 compared to PS1/Aph1a g-secretases,
although there were no signiﬁcant differences (Fig. 3f). PS2/Aph1aS
and PS2/Aph1b g-secretases showed higher efﬁciency of processing
Ab43 to Ab40 compared to PS1 g-secretases, though PS2/Aph1aS
didn't show signiﬁcant difference compared to PS1 g-secretases
(Fig. 3f).3.3. PS2/Aph1aS g-secretase cleaves less NICD in HEK293 cells
stably expressing 6 different g-secretase
We next tested the efﬁciency of Notch-cleavage by distinct g-
secretases using the above cell lines. Cells were transfected withNotchDE-eGFP [19], and 24 h after transfection, the cells were
collected and cell lysates were prepared. To assess the relative ac-
tivity of each g-secretase, the ratio of NICD-eGFP to NotchDE-eGFP
was determined by Western blot analysis. In all cell lines NICD-
eGFP was produced, but with different efﬁciencies. Aph1aL con-
taining g-secretase produced NICD-eGFP most efﬁciently, whereas
Aph1aS containing complexes were the least efﬁcient, especially
with PS2 (Fig. 4 a and b). Although these results slightly differ from
those observed in the yeast reporter assay, also in mammalian cells
different combinations of PSs and Aph1s affected Notch-cleavage
efﬁciency.
4. Discussion
A number of studies have reported that different g-secretases
have different substrate speciﬁcities and/or functional differences
[18,24,25]. To date, more than 90 g-secretase substrates are known,
including APP and Notch1 [26]. Thus, general g-secretase in-
hibitors, such as DAPT and L-685,458, suppress production of Ab,
NICD and all other substrates. Since NICD is needed for cell differ-
entiation and cell fate decision [27], inhibition of g-secretase-
induced NICD production causes severe side effects in vivo [28e30].
Recently, a phase III trial of a g-secretase inhibitor, semagacestat,
was terminated because of several adverse events, including skin
cancers and infections [31]. However, if different g-secretases have
different substrate speciﬁcities, it may be possible to develop a drug
that inhibits a speciﬁc g-secretase complex that cleaves APP but not
Notch1. Therefore, it is important to evaluate the substrate speci-
ﬁcities of the six different g-secretases (PS1 or PS2 with Aph1aS or
Aph1aL or Aph1b).
According to our Gal4 reporter assays, g-secretase complex with
PS2/Aph1b had a clear substrate speciﬁcity. When reconstituted in
yeast, which does not express endogenous g-secretase, all PS1 g-
secretases efﬁciently cleaved APP, whereas only PS2/Aph1b efﬁ-
ciently cleaved APP among PS2-containing complexes. In contrast,
all of the PS1-, but none of the PS2-containing complexes cleaved
Notch. Therefore, these results suggest that PS2/Aph1b g-secretase
cleaves APP, but not Notch. If this is the case in mammalian cells,
then PS2/Aph1b g-secretase may be an ideal therapeutic target,
since the inhibition of this g-secretase may suppress Ab production
without the severe side effects caused by inhibition of Notch sig-
nalling. However, our results in mammalian cells differed from
those observed in the yeast Gal4 reporter assays. Here PS2/Aph1aS
showed the lowest Notch-cleavage activity (see below). A possible
reason for this discrepancy is that yeast lacks additional proteins
which affect the g-secretase function of Notch processing and Ab
production. Several g-secretase-associated proteins, including
GSAP [32], CD147 [33], and CNTNAP1, COX4I1, CNTN1, and SYP [34],
do not exist in yeast. These proteins or other unknown binding
proteins might regulate cleavage-efﬁciencies of g-secretase sub-
strates, or might regulate localization of enzyme and/or substrate.
Using HEK293 cells stably expressing single g-secretase [18]
(Fig. 2), we analysed Ab production and Notch-cleavage by
distinct g-secretases. PS1/Aph1b g-secretase showed a higher
Ab42(43)/Ab40 compared to PS1/Aph1aL and PS1/Aph1aS g-sec-
retases, suggesting that Aph1b containing PS1 g-secretases slightly
shifts preference towards Ab42(43), as reported previously [25].
The higher Ab42(43)/Ab40 ratio produced by PS1/Aph1b g-secre-
tase is thought to be caused by a “closed” conformation of PS1,
which isn't observed in PS1/Aph1a g-secretase [24]. Several PS1
FAD mutations, which result in higher Ab42/Ab40 ratio, are also
reported to be in a “closed” conformation of PS1 [36]. In contrast, in
PS2 g-secretases the Aph1 isoform had no impact on the Ab42(43)/
Ab40 ratio, suggesting that all PS2 g-secretases are in a more
“closed” conformation, irrespective of Aph1. Another explanation
Fig. 3. Ab production and Ab species secreted by HEK293/Swe cells expressing distinct g-secretases. Ab levels secreted in during 6 h at 37 C were analysed. Media from
HEK293/Swe cells stably expressing distinct g-secretase subunits were collected after 6 h and subjected to ELISA for Ab40 (a), Аb42 (b), and Ab43 (c). Ab43 was not detectable in
PS2/Aph1aL samples. (d), The total Ab (Ab40 and Ab42 and Ab43) and (e), Ab42(43)/Ab40 ratios were calculated. (f), Ab40/Ab43 ratios were calculated. Ab40/Ab43 ratios for PS2/
Aph1aL g-secretase couldn't be calculated because the levels of Ab43 were undetectable. Statistical analysis was performed by one-way analysis of variance followed by Tukey's
multiple comparison test. The data are presented as means ± SD (n ¼ 3), *p < 0.05.
Fig. 4. NICD production in HEK293 cells expressing distinct g-secretase. HEK293 cells stably expressing distinct g-secretase subunits were transfected with NotchDE-eGFP using
Lipofectamine 2000. Cells were collected 24 h after transfection. a, cell lysates were prepared from the collected cells and subjected to Western blot to detect NotchDE-eGFP and
NICD-eGFP using anti GFP antibody. b, NICD-eGFP/NotchDE-eGFP ratios were calculated from three independent Western blot assays using Multi Gauge software. Statistical analysis
was performed by one-way analysis of variance followed by Tukey's multiple comparison test Error bars indicate SD. n ¼ 3 * p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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because recent paper showed restricted location of PS2 g-secretase,
which is different fromPS1, resulted in higher Ab42/Ab40 ratio [37].
We also checked whether conversion of Ab43 to Ab40 was affected
by different PSs and Aph1s. Previous experiments using cell culture
assays showed that PS2 g-secretases produced a ~1.5e2-fold
greater Ab40/Ab43 ratio than did PS1 g-secretases [25], implying
that PS2 g-secretases degrade Ab43 to Ab40 more efﬁciently than
do PS1 g-secretases. This tendency for accelerated processing of
Ab43 to Ab40 in PS2 g-secretases was also observed in our cell
culture assay (Fig. 3f), at least in the case of PS2/Aph1b and, less
pronounced, in PS2/Aph1aS complexes.
The Notch-cleavage efﬁciency of Aph1aS containing complexes
was lower than that of Aph1aL g-secretases, especially in combi-
nation with PS2, suggesting that Aph1aS is a determinant of
low Notch-cleavage speciﬁcity, considering that the different sub-
cellular localization of PS1 and PS2 didn't affect endogenous NICD
production [37]. Saito et al. reported that mRNA level of Aph1aS
was 1.5~3-fold higher than that of Aph1aL in HEK293 (~3-fold), SH-
SY5Y (~2.5-fold), Hela (1.5~2-fold) and human adult brain (2.5~3-
fold) [38], though it is unknown which combinations of g-secre-
tase are formed most prominently. It was reported that Aph1b g-
secretases might be a potential target of g-secretase inhibitors for
AD treatment because of their small side effects in knock-out
models [24], whereas Aph1a g-secretases shouldn't be the target
because of their important role in development [39]. Our results,
however, revealed that Aph1aS g-secretase cleaved Notch less
efﬁciently than Aph1aL, suggesting that it is rather Aph1aS that
should be targeted. In contrast, according to our data speciﬁc in-
hibition of Aph1b g-secretases might cause side effect because of
equal inhibition of APP and Notch signalling. Previous different
conclusion that Aph1b g-secretases play less important roles in
Notch-cleavage compared to Aph1a [24,39]might be explained as
follows. Knockdown of Aph1b is reported not to cause reduction of
the expression levels of other g-secretase components, implying
that Aph1a g-secretases still can work properly. In contrast,
knockdown of Aph1a caused marked reduction of expression level
of the other g-secretase components [18,40], suggesting that
Aph1b g-secretase formation is also affected.
In this manuscript, we showed that cells expressing PS2/Aph1aS
g-secretase produced Ab with higher Ab42(43)/40 ratio and lower
Notch-cleavage efﬁciency. However, this cell line contains only
a slight amount of PS1/Aph1aS g-secretase because cells expressing
PS2 g-secretase showed residual expression of PS1 and vice
versa, but importantly almost no residual Aph1 expression
(Supplementary Fig. S1). PS1/Aph1aS g-secretase showed lower
Ab42(43)/40 ratio and higher Notch-cleavage efﬁciency than PS2/
Aph1aS g-secretase. Therefore, pure PS2/Aph1aS g-secretase would
be expected to show even higher Ab42(43)/40 ratio and even lower
Notch.
In conclusion, we here show that the six distinct human g-sec-
retases have different cleavage-efﬁciencies for Notch and differ in
the Ab species they produce, though it is needed to analyse Notch-
cleavage and Ab production by the distinct g-secretases in neuronal
cells to conﬁrm that our ﬁndings are the case with the brain. Recent
studies revealed the PS1/Aph1aL g-secretase structure [41]. Further
analysis of different g-secretase structure might aid in the devel-
opment of structure-based speciﬁc g-secretase inhibitors. Targeting
the PS2/Aph1aS g-secretase complexwould be expected to have the
greatest effect of reducing Ab42(43)/Ab40 with the fewest side ef-
fects caused by inhibition of Notch signalling.
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